Full length interleukin 33 aggravates radiation-induced skin reaction

Frontiers in Immunology

Volumn 8, Issue JUN, 2017, Pages

  Kurow, Olga ^a   Frey, Benjamin ^a   Schuster, Louis ^a   Schmitt, Verena ^a   Adam, Susanne ^a   Hahn, Madelaine ^a   Gilchrist, Derek ^b   McInnes, Iain B ^b   Wirtz, Stefan ^a   Gaipl, Udo S ^a   Krönke, Gerhard ^a   Schett, Georg ^a   Frey, Silke ^a   Hueber, Axel J ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Dermatitis; Interleukin 33; Necrosis; Radiation; Skin inflammation

Indexed keywords

INTERLEUKIN 33;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL DERMATITIS; EXPERIMENTAL RADIATION INJURY; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMID; POLYADENYLATION; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; SKIN BIOPSY; SKINFOLD THICKNESS; WESTERN BLOTTING;

EID: 85021755870     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00722     Document Type: Article

References (48)

1. Smith DE. IL-33: a tissue derived cytokine pathway involved in allergic inflammation and asthma. Clin Exp Allergy (2010) 40(2):200-8. doi:10.1111/j.1365-2222.2009.03384.x
2. Louten J, Rankin AL, Li Y, Murphy EE, Beaumont M, Moon C, et al. Endogenous IL-33 enhances Th2 cytokine production and T-cell responses during allergic airway inflammation. Int Immunol (2011) 23(5):307-15. doi:10.1093/intimm/dxr006
3. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A (2013) 110(34):13921-6. doi:10.1073/pnas.1307321110
4. Alves-Filho JC, Sonego F, Souto FO, Freitas A, Verri WA Jr, Auxiliadora-Martins M, et al. Interleukin-33 attenuates sepsis by enhancing neutrophil influx to the site of infection. Nat Med (2010) 16(6):708-12. doi:10.1038/nm.2156
5. Millar NL, Gilchrist DS, Akbar M, Reilly JH, Kerr SC, Campbell AL, et al. MicroRNA29a regulates IL-33-mediated tissue remodelling in tendon disease. Nat Commun (2015) 6:6774. doi:10.1038/ncomms7774
6. Matsuyama Y, Okazaki H, Tamemoto H, Kimura H, Kamata Y, Nagatani K, et al. Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol (2010) 37(1):18-25. doi:10.3899/jrheum.090492
7. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al. IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur J Immunol (2011) 41(8):2229-37. doi:10.1002/eji.201041360
8. Pichery M, Mirey E, Mercier P, Lefrancais E, Dujardin A, Ortega N, et al. Endogenous IL-33 is highly expressed in mouse epithelial barrier tissues, lymphoid organs, brain, embryos, and inflamed tissues: in situ analysis using a novel Il-33-LacZ gene trap reporter strain. J Immunol (2012) 188(7):3488-95. doi:10.4049/jimmunol.1101977
9. Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol (2007) 179(4):2551-5. doi:10.4049/jimmunol.179.4.2551
10. Liu X, Hammel M, He YF, Tainer JA, Jeng US, Zhang LQ, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci U S A (2013) 110(37):14918-23. doi:10.1073/pnas.1308651110
11. Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity (2013) 39(6):1003-18. doi:10.1016/j.immuni.2013.11.010
12. Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'? PLoS One (2008) 3(10):e3331. doi:10.1371/journal.pone.0003331
13. Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci U S A (2007) 104(1):282-7. doi:10.1073/pnas.0606854104
14. Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, et al. The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol (2011) 187(4):1609-16. doi:10.4049/jimmunol.1003080
15. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A (2009) 106(22):9021-6. doi:10.1073/pnas.0812690106
16. Luthi AU, Cullen SP, McNeela EA, Duriez PJ, Afonina IS, Sheridan C, et al. Suppression of interleukin-33 bioactivity through proteolysis by apoptotic caspases. Immunity (2009) 31(1):84-98. doi:10.1016/j.immuni.2009.05.007
17. Lefrancais E, Roga S, Gautier V, Gonzalez-de-Peredo A, Monsarrat B, Girard JP, et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. Proc Natl Acad Sci U S A (2012) 109(5):1673-8. doi:10.1073/pnas.1115884109
18. Balato A, Lembo S, Mattii M, Schiattarella M, Marino R, De Paulis A, et al. IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation. Exp Dermatol (2012) 21(11):892-4. doi:10.1111/Exd.12027
19. Smithgall MD, Comeau MR, Yoon BR, Kaufman D, Armitage R, Smith DE. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol (2008) 20(8):1019-30. doi:10.1093/intimm/dxn060
20. Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol (2007) 179(4):2051-4. doi:10.4049/jimmunol.179.4.2051
21. Xu D, Jiang HR, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A (2008) 105(31):10913-8. doi:10.1073/pnas.0801898105
22. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production. Eur J Immunol (2009) 39(4):1046-55. doi:10.1002/eji.200838575
23. Palmer G, Talabot-Ayer D, Lamacchia C, Toy D, Seemayer CA, Viatte S, et al. Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis. Arthritis Rheum (2009) 60(3):738-49. doi:10.1002/art.24305
24. Ramasamy A, Kuokkanen M, Vedantam S, Gajdos ZK, Alves AC, Lyon HN, et al. Genome-wide association studies of asthma in population-based cohorts confirm known and suggested loci and identify an additional association near HLA. PLoS One (2012) 7(9):e44008. doi:10.1371/journal.pone.0044008
25. Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet (2014) 46(1):51-5. doi:10.1038/Ng.2830
26. Salimi M, Barlow JL, Saunders SP, Xue LZ, Gutowska-Owsiak D, Wang XW, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med (2013) 210(13):2939-50. doi:10.1084/Jem.20130351
27. McHedlidze T, Waldner M, Zopf S, Walker J, Rankin AL, Schuchmann M, et al. Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis. Immunity (2013) 39(2):357-71. doi:10.1016/j.immuni.2013.07.018
28. Vassar R, Rosenberg M, Ross S, Tyner A, Fuchs E. Tissue-specific and differentiation-specific expression of a human K14 keratin gene in transgenic mice. Proc Natl Acad Sci U S A (1989) 86(5):1563-7. doi:10.1073/pnas.86.5.1563
29. Nishijima T, Tokura Y, Imokawa G, Seo N, Furukawa F, Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J Invest Dermatol (1997) 109(2):175-82. doi:10.1111/1523-1747.ep12319282
30. Werthmoller N, Frey B, Wunderlich R, Fietkau R, Gaipl US. Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner. Cell Death Dis (2015) 6:e1761. doi:10.1038/cddis.2015.129
31. Chen AP, Setser A, Anadkat MJ, Cotliar J, Olsen EA, Garden BC, et al. Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0. J Am Acad Dermatol (2012) 67(5):1025-39. doi:10.1016/j.jaad.2012.02.010
32. Reisman SA, Lee CY, Meyer CJ, Proksch JW, Sonis ST, Ward KW. Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis. Radiat Res (2014) 181(5):512-20. doi:10.1667/RR13578.1
33. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med (2006) 203(12):2577-87. doi:10.1084/Jem.20060244
34. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu JF, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature (2007) 445(7128):648-51. doi:10.1038/Nature05505
35. Cayrol C, Girard JP. IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. Curr Opin Immunol (2014) 31:31-7. doi:10.1016/j.coi.2014.09.004
36. Lunderius-Andersson C, Enoksson M, Nilsson G. Mast cells respond to cell injury through the recognition of IL-33. Front Immunol (2012) 3:82. doi:10.3389/fimmu.2012.00082
37. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci U S A (2010) 107(25):11489-94. doi:10.1073/pnas.1003988107
38. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol (2011) 12(11):1055-62. doi:10.1038/ni.2104
39. Walker JA, McKenzie AN. Development and function of group 2 innate lymphoid cells. Curr Opin Immunol (2013) 25(2):148-55. doi:10.1016/j.coi.2013.02.010
40. Nussbaum JC, Van Dyken SJ, von Moltke J, Cheng LE, Mohapatra A, Molofsky AB, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature (2013) 502(7470):245-8. doi:10.1038/nature12526
41. Lott J, Liu Q, Matta B, Mathews L, Pociask D, Sperling A, et al. The iron sequestering protein lipocalin 2 is critical to IL-33-exposed dendritic cell stimulation of Th2 responses and allergic airway disease (IRC7P.424). J Immunol (2015) 194(1 Suppl):128.5.
42. Liew FY. IL-33: a Janus cytokine. Ann Rheum Dis (2012) 71(Suppl 2):i101-4. doi:10.1136/annrheumdis-2011-200589
43. Ha CT, Li XH, Fu DD, Xiao M, Landauer MR. Genistein nanoparticles protect mouse hematopoietic system and prevent proinflammatory factors after gamma irradiation. Radiat Res (2013) 180(3):316-25. doi:10.1667/RR3326.1
44. Ha CT, Li XH, Fu D, Moroni M, Fisher C, Arnott R, et al. Circulating interleukin-18 as a biomarker of total-body radiation exposure in mice, minipigs, and nonhuman primates (NHP). PLoS One (2014) 9(10):e109249. doi:10.1371/journal.pone.0109249
45. Lee EJ, Kim JW, Yoo H, Kwak W, Choi WH, Cho S, et al. Single high-dose irradiation aggravates eosinophil-mediated fibrosis through IL-33 secreted from impaired vessels in the skin compared to fractionated irradiation. Biochem Biophys Res Commun (2015) 464(1):20-6. doi:10.1016/j.bbrc.2015.05.081
46. Ivanov VN, Zhou H, Ghandhi SA, Karasic TB, Yaghoubian B, Amundson SA, et al. Radiation-induced bystander signaling pathways in human fibroblasts: a role for interleukin-33 in the signal transmission. Cell Signal (2010) 22(7):1076-87. doi:10.1016/j.cellsig.2010.02.010
47. Rankin AL, Mumm JB, Murphy E, Turner S, Yu N, McClanahan TK, et al. IL-33 induces IL-13-dependent cutaneous fibrosis. J Immunol (2010) 184(3):1526-35. doi:10.4049/jimmunol.0903306
48. Yin H, Li X, Hu S, Liu T, Yuan B, Gu H, et al. IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol (2013) 56(4):347-53. doi:10.1016/j.molimm.2013.05.225